272 related articles for article (PubMed ID: 18639646)
21. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
[TBL] [Abstract][Full Text] [Related]
22. Discovery of cyclin-dependent kinase inhibitor, CR229, using structurebased drug screening.
Kim MK; Min J; Choi BY; Lim H; Cho YH; Lee CH
J Microbiol Biotechnol; 2007 Oct; 17(10):1712-6. PubMed ID: 18156791
[TBL] [Abstract][Full Text] [Related]
23. Synthesis of 1,7-annulated indoles and their applications in the studies of cyclin dependent kinase inhibitors.
Zhu G; Conner SE; Zhou X; Chan HK; Shih C; Engler TA; Al-Awar RS; Brooks HB; Watkins SA; Spencer CD; Schultz RM; Dempsey JA; Considine EL; Patel BR; Ogg CA; Vasudevan V; Lytle ML
Bioorg Med Chem Lett; 2004 Jun; 14(12):3057-61. PubMed ID: 15149644
[TBL] [Abstract][Full Text] [Related]
24. Anticancer activity and differentially expressed genes in head and neck cancer cells treated with a novel cyclin-dependent kinase inhibitor.
Shin HC; Song DW; Baek WK; Lee SR; Kwon TK; Lee J; Park SH; Jang BC; Park JW
Chemotherapy; 2009; 55(5):353-62. PubMed ID: 19657189
[TBL] [Abstract][Full Text] [Related]
25. [Prevention of chemotherapy-induced alopecia by cyclin-dependant kinase inhibitors].
Meijer L; Knockaert M; Damiens E
Bull Cancer; 2001 Apr; 88(4):347-50. PubMed ID: 11371368
[TBL] [Abstract][Full Text] [Related]
26. Targeting the cell cycle: a new approach to cancer therapy.
Schwartz GK; Shah MA
J Clin Oncol; 2005 Dec; 23(36):9408-21. PubMed ID: 16361640
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological evaluation of 3,5-diaminoindazoles as cyclin-dependent kinase inhibitors.
Lee J; Choi H; Kim KH; Jeong S; Park JW; Baek CS; Lee SH
Bioorg Med Chem Lett; 2008 Apr; 18(7):2292-5. PubMed ID: 18353638
[TBL] [Abstract][Full Text] [Related]
28. The role of cyclin-dependent kinases in apoptosis.
Borgne A; Golsteyn RM
Prog Cell Cycle Res; 2003; 5():453-9. PubMed ID: 14593740
[TBL] [Abstract][Full Text] [Related]
29. Cyclin-dependent kinase inhibitors block erythrocyte invasion and intraerythrocytic development of Babesia bovis in vitro.
Nakamura K; Yokoyama N; Igarashi I
Parasitology; 2007 Sep; 134(Pt 10):1347-53. PubMed ID: 17634158
[TBL] [Abstract][Full Text] [Related]
30. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
Abate AA; Pentimalli F; Esposito L; Giordano A
Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075
[TBL] [Abstract][Full Text] [Related]
31. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
Malínková V; Vylíčil J; Kryštof V
Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.
Lin R; Connolly PJ; Lu Y; Chiu G; Li S; Yu Y; Huang S; Li X; Emanuel SL; Middleton SA; Gruninger RH; Adams M; Fuentes-Pesquera AR; Greenberger LM
Bioorg Med Chem Lett; 2007 Aug; 17(15):4297-302. PubMed ID: 17532631
[TBL] [Abstract][Full Text] [Related]
33. Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer.
Goel B; Tripathi N; Bhardwaj N; Jain SK
Curr Top Med Chem; 2020; 20(17):1535-1563. PubMed ID: 32416692
[TBL] [Abstract][Full Text] [Related]
34. Inhibiting transient protein-protein interactions: lessons from the Cdc25 protein tyrosine phosphatases.
Rudolph J
Nat Rev Cancer; 2007 Mar; 7(3):202-11. PubMed ID: 17287826
[TBL] [Abstract][Full Text] [Related]
35. Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia?
Wesierska-Gadek J; Krystof V
Ann N Y Acad Sci; 2009 Aug; 1171():228-41. PubMed ID: 19723060
[TBL] [Abstract][Full Text] [Related]
36. 3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation.
Lin R; Lu Y; Wetter SK; Connolly PJ; Turchi IJ; Murray WV; Emanuel SL; Gruninger RH; Fuentes-Pesquera AR; Adams M; Pandey N; Moreno-Mazza S; Middleton SA; Jolliffe LK
Bioorg Med Chem Lett; 2005 May; 15(9):2221-4. PubMed ID: 15837297
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in CDK inhibitors for cancer therapy.
Heptinstall AB; Adiyasa I; Cano C; Hardcastle IR
Future Med Chem; 2018 Jun; 10(11):1369-1388. PubMed ID: 29846081
[TBL] [Abstract][Full Text] [Related]
38. A proteome-wide CDK/CRK-specific kinase inhibitor promotes tumor cell death in the absence of cell cycle progression.
Caligiuri M; Becker F; Murthi K; Kaplan F; Dedier S; Kaufmann C; Machl A; Zybarth G; Richard J; Bockovich N; Kluge A; Kley N
Chem Biol; 2005 Oct; 12(10):1103-15. PubMed ID: 16242653
[TBL] [Abstract][Full Text] [Related]
39. Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors.
Jessen BA; Lee L; Koudriakova T; Haines M; Lundgren K; Price S; Nonomiya J; Lewis C; Stevens GJ
J Appl Toxicol; 2007; 27(2):133-42. PubMed ID: 17211896
[TBL] [Abstract][Full Text] [Related]
40. Cyclin-dependent kinase inhibitors closer to market launch?
Galons H; Oumata N; Gloulou O; Meijer L
Expert Opin Ther Pat; 2013 Aug; 23(8):945-63. PubMed ID: 23600454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
